Clinical Trials Logo

Clinical Trial Summary

Study to compare PK of a new 100mg capsule with four 25mg capsules. This is required because we plan to have only single capsules administered in the later phase clinical trials but we have not had a 100mg strength before. As this is a new previously untested strength we need to ensure that the PK is similar to that achieved using 4 x 25mg. The study will also assess the effect of high fat food on the PK of the 100mg capsule. The study is planned to consist of a single part , with three dosing periods, periods 1-3 consisting of 16 subjects. There will be a week wash out between each dose. In the three dosing periods subjects will either received 4x25 mg GSK598809 capsule in a fasted state, 100mg capsule in a fasted state or 100mg GSK598809 capsule in a fed state. Subjects will return to the centre for follow-up 7-14 days after the final dose. It is expected that the total duration of the study should be approximately eight weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00728897
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date July 2, 2008
Completion date July 29, 2008

See also
  Status Clinical Trial Phase
Completed NCT00887367 - EtOH Interaction Study Phase 1
Completed NCT01036061 - GSK618334 Repeat Dose Study Phase 1
Completed NCT01189799 - Motivational Therapy for Substance Users With Depression N/A
Completed NCT01381133 - Adolescent Outpatient and Continuing Care Study Phase 3
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT01128140 - Efficacy Trial of Warrior Check-Up Phase 2
Completed NCT03767907 - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial N/A
Recruiting NCT05833399 - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn NCT01515917 - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI) N/A
Completed NCT00208143 - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Phase 4
Withdrawn NCT03762798 - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone N/A
Completed NCT03048552 - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 N/A
Active, not recruiting NCT04768920 - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) N/A
Recruiting NCT05410561 - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients N/A
Recruiting NCT05679284 - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn NCT00908206 - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics Phase 1
Recruiting NCT05348317 - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders N/A
Recruiting NCT01741415 - Distress Tolerance Treatment for Substance Users Phase 2
Active, not recruiting NCT01621711 - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2